Anika Therapeutics (NASDAQ:ANIK - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Wednesday, July 30th. Analysts expect Anika Therapeutics to post earnings of ($0.13) per share and revenue of $27.03 million for the quarter.
Anika Therapeutics Stock Performance
Anika Therapeutics stock opened at $11.04 on Wednesday. The firm's fifty day moving average price is $11.29 and its 200-day moving average price is $14.22. The stock has a market cap of $158.24 million, a P/E ratio of -2.84 and a beta of 0.64. Anika Therapeutics has a fifty-two week low of $10.47 and a fifty-two week high of $28.60.
Hedge Funds Weigh In On Anika Therapeutics
A hedge fund recently bought a new stake in Anika Therapeutics stock. AQR Capital Management LLC bought a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,057 shares of the biotechnology company's stock, valued at approximately $181,000. AQR Capital Management LLC owned about 0.08% of Anika Therapeutics as of its most recent SEC filing. 91.53% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
ANIK has been the subject of several recent analyst reports. B. Riley began coverage on shares of Anika Therapeutics in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price for the company. Barrington Research decreased their price objective on shares of Anika Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Monday, May 12th. Finally, Wall Street Zen cut shares of Anika Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 12th.
Get Our Latest Report on ANIK
About Anika Therapeutics
(
Get Free Report)
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
